Heini Lassus1, Synnöve Staff, Arto Leminen, Jorma Isola, Ralf Butzow. 1. Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Hospital District of Helsinki and Uusimaa, Research Laboratory, Biomedicum Helsinki, P.O. Box 700 (Haartmanink. 8), FIN-00029 HUS, Finland.
Abstract
OBJECTIVE: Aurora-A is a potential oncogene and therapeutic target in ovarian carcinoma. It is involved in mitotic events and overexpression leads to centrosome amplification and chromosomal instability. The objective of this study was to evaluate the clinical significance of Aurora-A and DNA ploidy in serous ovarian carcinoma. METHODS: Serous ovarian carcinomas were analysed for Aurora-A protein by immunohistochemistry (n=592), Aurora-A copy number by CISH (n=169), Aurora-A mRNA by real-time PCR (n=158) and DNA ploidy by flowcytometry (n=440). RESULTS: Overexpression of Aurora-A was found in 27% of the tumors, cytoplasmic overexpression in 11% and nuclear in 17%. The cytoplasmic and nuclear overexpression were nearly mutually exclusive. Both cytoplasmic and nuclear overexpression were associated with shorter survival, high grade, high proliferation index and aberrant p53. Interestingly, only cytoplasmic expression was associated with aneuploidy and expression of phosphorylated Aurora-A. DNA ploidy was associated with poor patient outcome as well as aggressive clinicopathological parameters. In multivariate analysis, Aurora-A overexpression appeared as an independent prognostic factor for disease-free survival, together with grade, stage and ploidy. CONCLUSIONS: Aurora-A protein expression is strongly linked with poor patient outcome and aggressive disease characteristics, which makes Aurora-A a promising biomarker and a potential therapeutic target in ovarian carcinoma. Cytoplasmic and nuclear Aurora-A protein may have different functions. DNA aneuploidy is a strong predictor of poor prognosis in serous ovarian carcinoma.
OBJECTIVE:Aurora-A is a potential oncogene and therapeutic target in ovarian carcinoma. It is involved in mitotic events and overexpression leads to centrosome amplification and chromosomal instability. The objective of this study was to evaluate the clinical significance of Aurora-A and DNA ploidy in serous ovarian carcinoma. METHODS:Serous ovarian carcinomas were analysed for Aurora-A protein by immunohistochemistry (n=592), Aurora-A copy number by CISH (n=169), Aurora-A mRNA by real-time PCR (n=158) and DNA ploidy by flowcytometry (n=440). RESULTS: Overexpression of Aurora-A was found in 27% of the tumors, cytoplasmic overexpression in 11% and nuclear in 17%. The cytoplasmic and nuclear overexpression were nearly mutually exclusive. Both cytoplasmic and nuclear overexpression were associated with shorter survival, high grade, high proliferation index and aberrant p53. Interestingly, only cytoplasmic expression was associated with aneuploidy and expression of phosphorylated Aurora-A. DNA ploidy was associated with poor patient outcome as well as aggressive clinicopathological parameters. In multivariate analysis, Aurora-A overexpression appeared as an independent prognostic factor for disease-free survival, together with grade, stage and ploidy. CONCLUSIONS:Aurora-A protein expression is strongly linked with poor patient outcome and aggressive disease characteristics, which makes Aurora-A a promising biomarker and a potential therapeutic target in ovarian carcinoma. Cytoplasmic and nuclear Aurora-A protein may have different functions. DNA aneuploidy is a strong predictor of poor prognosis in serous ovarian carcinoma.
Authors: Suzanne M Quartuccio; Subbulakshmi Karthikeyan; Sharon L Eddie; Daniel D Lantvit; Eoghainín Ó hAinmhire; Dimple A Modi; Jian-Jun Wei; Joanna E Burdette Journal: Int J Cancer Date: 2015-04-11 Impact factor: 7.396
Authors: Kristen N Stevens; Linda E Kelemen; Xianshu Wang; Brooke L Fridley; Robert A Vierkant; Zachary Fredericksen; Sebastian M Armasu; Ya-Yu Tsai; Andrew Berchuck; Steven A Narod; Catherine M Phelan; Rebecca Sutphen; Michael J Birrer; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode; Fergus J Couch Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-01-17 Impact factor: 4.254
Authors: Jeremy Chien; Hugues Sicotte; Jian-Bing Fan; Sean Humphray; Julie M Cunningham; Kimberly R Kalli; Ann L Oberg; Steven N Hart; Ying Li; Jaime I Davila; Saurabh Baheti; Chen Wang; Sabine Dietmann; Elizabeth J Atkinson; Yan W Asmann; Debra A Bell; Takayo Ota; Yaman Tarabishy; Rui Kuang; Marina Bibikova; R Keira Cheetham; Russell J Grocock; Elizabeth M Swisher; John Peden; David Bentley; Jean-Pierre A Kocher; Scott H Kaufmann; Lynn C Hartmann; Viji Shridhar; Ellen L Goode Journal: Nucleic Acids Res Date: 2015-04-27 Impact factor: 16.971
Authors: T-V Do; F Xiao; L E Bickel; A J Klein-Szanto; H B Pathak; X Hua; C Howe; S W O'Brien; M Maglaty; J A Ecsedy; S Litwin; E A Golemis; R J Schilder; A K Godwin; D C Connolly Journal: Oncogene Date: 2013-01-21 Impact factor: 9.867
Authors: Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis Journal: Cell Mol Life Sci Date: 2012-08-03 Impact factor: 9.261
Authors: Nicole F Neel; Jeran K Stratford; Vaishali Shinde; Jeffrey A Ecsedy; Timothy D Martin; Channing J Der; Jen Jen Yeh Journal: Mol Cancer Ther Date: 2013-11-12 Impact factor: 6.261